|
| |
angiocept Pages on BioPortfolio:
BioPortfolio - angiocept
BioPortfolio - angiocept BioPortfolio - Vascular Endothelial Growth Factor ... BioPortfolio - fgfr2 antibody BioPortfolio - angiocept BioPortfolio - brain .
...
http://www.bioportfolio.com/search/angiocept.html...
|
BioPortfolio - Adnexus Therapeutics, Inc.
Angiocept™ (CT-322), an AdNectin that inhibits the activation of human vascular ... Angiocept (CT-322) is scheduled to begin Phase I clinical studies in ...
http://www.bioportfolio.com/biocorporate/21203-Adnexus_Thera...
|
BioPortfolio - Vascular Therapeutics
BioPortfolio - Vascular Therapeutics Incorporated CT-322 (Angiocept; Adnexus Therapeutics Inc), ... http://www.bioportfolio.com/search/angiocept.html. ...
http://www.bioportfolio.com/search/Vascular_Therapeutics.htm...
|
BioPortfolio - Adnexus Therapeutics, Inc. - Profile
Angiocept™ (CT-322), an AdNectin that. inhibits the activation of human vascular endothelial growth ... Angiocept (CT-322) is scheduled to begin Phase I ...
http://www.bioportfolio.com/biocorporate/21203-Adnexus+Thera...
|
BioPortfolio - IBC USA c
BioPortfolio - IBC us Adnexus’ first product candidate, Angiocept (CT-322), ... Angiocept (CT-322) is ... BioPortfolio - ibc us BioPortfolio - IBC USA c . ...
http://www.bioportfolio.com/search/IBC_USA_c.html...
|
BioPortfolio - fgfr2 antibody
BioPortfolio - fgfr2 antibody BioPortfolio - angiocept BioPortfolio - brain specific angiogenesis ... http://www.bioportfolio.com/search/angiocept.html. ...
http://www.bioportfolio.com/search/fgfr2_antibody.html...
|
BioPortfolio - Vascular Endothelial Growth Factor Receptor-2
BioPortfolio - angiocept BioPortfolio - Vascular Endothelial Growth Factor Receptor-2 BioPortfolio ... http://www.bioportfolio.com/search/angiocept.html.
...
http://www.bioportfolio.com/search/Vascular_Endothelial_Grow...
|
BioPortfolio - ibc usa
BioPortfolio - IBC us Adnexus’ first product candidate, Angiocept (CT-322), is in U.S. ... Adnexus Therapeutics Raises $15.5 Million in Series C Funding . ...
http://www.bioportfolio.com/search/_ibc_usa_.html...
|
BioPortfolio - usa conferences
BioPortfolio - ibc usa conferences BioPortfolio - IBC us Adnexus’ first product candidate, ... http://www.bioportfolio.com/search/angiocept.html. ...
http://www.bioportfolio.com/search/usa_conferences.html...
|
BioPortfolio - ibc-us
BioPortfolio - IBC us Adnexus’ first product candidate, Angiocept (CT-322), . .. . http://www.bioportfolio.com/search/ibc_usa_conferences.html. ...
http://www.bioportfolio.com/search/ibc-us.html...
|
Results from other life science and pharmaceutical sites:
BioPortfolio - angiocept
BioPortfolio - angiocept BioPortfolio - Vascular Endothelial Growth Factor ... BioPortfolio - fgfr2 antibody BioPortfolio - angiocept BioPortfolio - brain .
...
http://www.bioportfolio.com/search/angiocept.html...
|
Sigal - Investment Community Meeting
Angiocept (Cancer). (Cancer). • Brivanib. Brivanib-VEGFR/FGFR Inhibitor ... Angiocept. Potent and specific antagonist of VEGFR-2 ...
http://www.bms.com/irdocs/sigal3_ICM.pdf...
|
BioSpace - Print News Article
Angiocept is an Adnectin designed to be an anti-angiogenic drug and is ... In addition, the Phase 1 oncology biologic described in this release, Angiocept,
...
http://www.biospace.com/news_print.aspx?NewsEntityId=70760...
|
Sigal - Investment Community Meeting
Angiocept (Cancer). (Cancer). • Brivanib. Brivanib-VEGFR/FGFR Inhibitor. VEGFR/ FGFR Inhibitor (Cancer). (Cancer). • ErbB. ErbB/VEGF Receptor Inhibitor ...
http://www.bms.com/irdocs/sigal2_ICM.pdf...
|
Bristol-Myers Squibb to Buy Partner Adnexus Therapeutics for $430 ...
Adnexus' lead product candidate, Angiocept (CT-322), is in Phase 1 clinical development in oncology in the United States. The company also has a pipeline of
...
http://www.biospace.com/news_story.aspx?NewsEntityId=70760...
|
BioPortfolio - Adnexus Therapeutics, Inc.
Angiocept™ (CT-322), an AdNectin that inhibits the activation of human vascular ... Angiocept (CT-322) is scheduled to begin Phase I clinical studies in ...
http://www.bioportfolio.com/biocorporate/21203-Adnexus_Thera...
|
Adnexus Therapeutics Raises $15.5 Million in Series C Funding ...
"During the past year, we established our first strategic alliance, with Bristol -Myers Squibb, and we advanced the Phase 1 development of Angiocept(TM). ...
http://www.biospace.com/news_story.aspx?NewsEntityId=66024...
|
Sigal - Investment Community Meeting
Angiocept. (Cancer). Anti-CD137. (Cancer). Devens Bulk. Manufacturing. Syracuse ... Adnexus’ lead product, Angiocept, in Phase II. Adnexus: The Opportunity ...
http://www.bms.com/irdocs/sigal_ICM.pdf...
|
BioPortfolio - Adnexus Therapeutics, Inc. - Profile
Angiocept™ (CT-322), an AdNectin that. inhibits the activation of human vascular endothelial growth ... Angiocept (CT-322) is scheduled to begin Phase I ...
http://www.bioportfolio.com/biocorporate/21203-Adnexus+Thera...
|
Daniels - Investment Community Meeting
•Angiocept. •ErbB/VEGF. inhibitor. •Erbitux. •Sprycel. •IGF-1R. antagonist. •Met kinase. inhibitor. •SMO inhibitor. •Hsp90 inhibitor. •Ixempra. •Epothilone- ...
http://www.bms.com/irdocs/daniels_ICM.pdf...
|
|
